Results 1 to 10 of about 1,418,021 (124)

Management of moderate to severe chronic low back pain with buprenorphine buccal film using novel bioerodible mucoadhesive technology [PDF]

Journal of Pain Research, 2016
Joseph V Pergolizzi Jr,1 Robert B Raffa,2,3 Charles Fleischer,1 Gianpietro Zampogna,1 Robert Taylor Jr1 1NEMA Research, Naples, FL, 2University of Arizona College of Pharmacy, Tucson, AZ, 3Temple University School of Pharmacy, Philadelphia, PA, USA ...
Pergolizzi Jr JV, Raffa RB, Fleischer C, Zampogna G, Taylor R Jr   +4 more
doaj   +5 more sources

Long-term safety and analgesic efficacy of buprenorphine buccal film in patients with moderate-to-severe chronic pain requiring around-the-clock opioids [PDF]

Journal of Pain Research, 2017
Martin Hale,1 Veronica Urdaneta,2 M Todd Kirby,3 Qinfang Xiang,4 Richard Rauck5 1Gold Coast Research, LLC, Plantation, FL, USA; 2Pharmacovigilance and Risk Management, 3Clinical Development, 4Biometrics, Endo Pharmaceuticals Inc., Malvern, PA, USA ...
Hale M, Urdaneta V, Kirby MT, Xiang Q, Rauck R   +4 more
doaj   +3 more sources

Economic and Treatment Burden of Chronic Low-Back Pain Patients Transitioning from Short-Acting to Long-Acting Opioids or Buprenorphine Buccal Film: US Claims Analysis [PDF]

Pain and Therapy
Introduction This study aimed to assess economic burden and treatment characteristics of patients with chronic low-back pain (cLBP) transitioning from oral Schedule II (CII) short-acting opioids (SAO) to oral CII long-acting opioids (LAO) or Belbuca ...
Filip Stanicic, Dimitrije Grbic, Vladimir Zah   +2 more
doaj   +3 more sources

Buprenorphine Products for the Treatment of Pain: Relative Risk of Abuse and Related Clinical Outcomes Compared to Full μ-Opioid Agonist Medications [PDF]

Pain and Therapy
Introduction The objective of this study was to utilize real-world data from National Poison Data System (NPDS) to evaluate the relative risk of intentional use and subsequent outcomes following exposures to buprenorphine buccal film (BBF) compared to ...
Jody L. Green, Taryn Dailey-Govoni, Suzanne K. Vosburg   +2 more
doaj   +2 more sources

Treatment characteristics and safety profiles of Belbuca®, buprenorphine patch, and oral schedule II opioids among chronic low back pain patients without a positive history of opioid-use disorder: a retrospective US commercial claims analysis [PDF]

Frontiers in Pain Research
IntroductionThe objective of this retrospective study was to evaluate and compare the safety characteristics of patients with chronic low back pain (cLBP) without a recent positive history of opioid use disorder (OUD).MethodsThis study was conducted ...
Vladimir Zah, Dimitrije Grbic, Filip Stanicic   +2 more
doaj   +2 more sources

Buprenorphine Use for Analgesia in Palliative Care [PDF]

Pharmacy
Buprenorphine is a semi-synthetic long-acting partial µ-opioid receptor (MOR) agonist that can be used for chronic pain as a sublingual tablet, transdermal patch (Butrans®), or a buccal film (Belbuca®).
Leanne K. Jackson, Ivy O. Poon, Mary A. Garcia, Syed Imam, Ursula K. Braun   +4 more
doaj   +2 more sources

Benefit-Risk Analysis of Buprenorphine for Pain Management

Journal of Pain Research, 2021
Martin Hale,1 Mark Garofoli,2 Robert B Raffa3,4 1Gold Coast Research, LLC, Plantation, FL, 33317, USA; 2Department of Clinical Pharmacy, West Virginia University School of Pharmacy, Morgantown, WV, 26505, USA; 3University of Arizona College of Pharmacy ...
Hale M, Garofoli M, Raffa RB
doaj   +2 more sources

Mucoadhesive Drug Delivery Systems for Oral Chronic Inflammatory Mucosal Diseases. The Future is Already Present. A Systematic Review [PDF]

Oral Diseases, Volume 32, Issue 1, Page 25-36, January 2026.
ABSTRACT Background Oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS) are considered the most painful oral inflammatory diseases, with high global prevalence and significant impacts on patients' quality of life. In the last decades, researchers have been exploring mucoadhesive drug delivery systems (MDDS) to improve drugs safety and ...
M. E. Mauceri, M. Coppini, V. De Caro, G. Di Prima, R. Mauceri, V. Panzarella, G. Giuliana, G. Campisi   +7 more
wiley   +2 more sources

Serious treatment-emergent adverse events in chronic low back pain patients treated with buprenorphine or oral opioids: a retrospective commercial claims analysis [PDF]

Journal of Comparative Effectiveness Research
Aim: Explore the safety of Belbuca (buprenorphine buccal film), buprenorphine transdermal patches and oral opioids for chronic low back pain (cLBP) treatment.
Filip Stanicic, Dimitrije Grbic, Djurdja Vukicevic, Vladimir Zah   +3 more
doaj   +2 more sources

Pharmacokinetics of Buprenorphine Buccal Film and Orally-administered Oxycodone in a Respiratory Study: An Analysis of Secondary Outcomes from a Randomized Controlled Trial [PDF]

Pain and Therapy, 2022
Lynn Webster
exaly   +2 more sources